Guidelines for the prevention and treatment of atherosclerosis and cardiovascular diseases: General recommendations - Hypertension

Harefuah

Volumn 144, Issue 7, 2005, Pages 506-512

  Bitzur, Rafael ^a   Harats, Dror ^a   Rubinstein, Ardon ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Dyslipidemia; Hypertension; Ischemic heart disease; Obesity; Stroke

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; MEDICAL PRACTICE; PATIENT CARE; PRACTICE GUIDELINE; ARTERIOSCLEROSIS; HEALTH CARE QUALITY; ISRAEL;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; ISRAEL; QUALITY ASSURANCE, HEALTH CARE;

EID: 24344468322     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Grundy SM, Cleeman JI, Bairey Merz CN & al, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004; 110: 227-239.
2. De Backer G, Ambrosioni E, Borch-Johnsen K & al, European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003; 24: 1601-1610.
3. Conroy RM, Pyörälä K, Fitzgerald AP & al, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 2003; 24: 987-1003.
4. Cannon CP, Braunwald E, McCabe CH & al, Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med, 2004; 350: 1495-1504.
5. Nissen SE, Tuzcu EM, Schoenhagen P & al, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291: 1071-1080.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22.
7. Sever PS, Dahlof B, Poulter NR & al, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-58.
8. Shepherd J, Blauw GJ, Murphy MB & al, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet, 2002; 360: 1623-1630.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002; 288: 2998-3007.
10. Harats D & Rubinstein A, Joint recommendations of Israel medical societies for prevention of coronary heart disease and atherosclerosis. Harefuah, 2000; 138: 66-74.
11. Menotti A, Lanti M, Puddu PE & Kromhout D, Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart, 2000; 84: 238-244.
12. Berlin JA & Colditz GA, A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol, 1990; 132: 612-628.
13. Thune I, Brenn T, Lund E & Gaard M , Physical activity and the risk of breast cancer. N Engl J Med, 1997; 336: 1269-1275.
14. Prince RL, Smith M, Dick IM & al, Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med, 1991; 325: 1189-1195.
15. Jakicic JM, Marcus BH, Gallagher KI & al, Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA, 2003; 290: 1323-1330.
16. Duncan JJ, Farr JE, Upton SJ & al, The effects of aerobic exercise on plasma catecholamines and blood pressure in patients with mild essential hypertension. JAMA, 1985; 254: 2609-2613.
17. Kraus WE, Houmard JA, Duscha BD & al, Effects of the Amount and Intensity of Exercise on Plasma Lipoproteins. N Engl J Med, 2002; 347: 1483-1492.
18. Hubert HB, Feinleib M, McNamara PM & Castelli WP, Obesity as an independent risk factor for cardiovascular disease: 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983; 67: 968-977.
19. Xavier Pi-Sunyer F, Medical hazards of obesity. Ann Int Med, 1993; 119: 655-660.
20. Manson JE, Colditz GA, Stampfer MJ & al, A prospective study of obesity and risk of coronary heart disease in women. N Eng J Med, 1990; 322: 882-889.
21. Durazo-Arvizu RA, McGee DL, Cooper RS & al, Mortality and optimal body mass index in a sample of the US population, Am J Epidemiol, 1998; 147: 739-749.
22. Diverse Populations Collaborative Group. Weight-Height Relationships and Body Mass Index: Some Observations from the Diverse Population Collaboration. Am J Phys Anthropol, 2004 (in press).
23. Chobanian AV, Bakris GL, Black HR & al, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 2003; 289: 2560-2571.
24. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension, 2003; 21: 1011-1053.